The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity
- 18 June 2007
- journal article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 26 (57), 7833-7846
- https://doi.org/10.1038/sj.onc.1210590
Abstract
Physiological signalling by the epidermal growth factor receptor ( EGFR) controls developmental processes and tissue homeostasis, whereas aberrant EGFR activity drives oncogenic cell transformation. Under normal conditions, the EGFR must therefore generate outputs of defined strength and duration. To this aim, cells balance EGFR activity via different modalities of negative signalling. Increasing attention is being drawn on transcriptionally controlled feedback inhibitors of EGFR, namely RALT/MIG6, LRIG1, SOCS4 and SOCS5. Genetic studies in mice have revealed the essential role of Ralt/Mig6 in regulating Egfr-driven skin morphogenesis and tumour formation, yet the mechanisms through which RALT abrogates EGFR activity are still undefined. We report that RALT suppresses EGFR function by inhibiting its catalytic activity. The evolutionarily conserved ErbB-binding region (EBR) is necessary and sufficient to carry out RALT-dependent suppression of EGFR kinase activity in vitro and in intact cells. The mechanism involves binding of the EBR to the 953RYLVIQ958 sequence, which is located in the alpha I helix of the EGFR kinase and has been shown to participate in allosteric control of EGFR catalytic activity. Our results uncover a novel mechanism of temporal regulation of EGFR activity in vertebrate organisms.status: publisheKeywords
This publication has 37 references indexed in Scilit:
- Evidence that MIG-6 is a tumor-suppressor geneOncogene, 2006
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and MitogenicityJournal of Biological Chemistry, 2005
- Gene 33 Is an Endogenous Inhibitor of Epidermal Growth Factor (EGF) Receptor Signaling and Mediates Dexamethasone-induced Suppression of EGF FunctionPublished by Elsevier BV ,2005
- Endocytosis and cancerCurrent Opinion in Cell Biology, 2004
- Inhibition of Insulin Receptor Catalytic Activity by the Molecular Adapter Grb14Published by Elsevier BV ,2002
- Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimersThe EMBO Journal, 1998
- All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis ImpairedPublished by Elsevier BV ,1996
- EGF Receptor and erb B-2 Tyrosine Kinase Domains Confer Cell Specificity for Mitogenic SignalingScience, 1990